From rockets to medicines: Huntsville's next frontier is biopharma

Huntsville, Alabama built its reputation by helping America reach space. Now, the city known for rockets, engineering and advanced manufacturing is helping chart another frontier: biopharmaceutical innovation.

The Rocket City is emerging as part of a new generation of U.S. biopharma hubs, as research institutions, skilled talent and advanced manufacturing capabilities create opportunities for medicine development and production.

Here's the deal: Eli Lilly and Company's planned $6 billion active pharmaceutical ingredient manufacturing facility in Huntsville is the latest signal of that momentum.

• The new facility will manufacture small molecule synthetic and peptide medicines, including orforglipron, Lilly's oral GLP-1 receptor agonist. Construction is expected to begin in 2026, with completion planned for 2032.

The benefits: Increasing U.S. API manufacturing can help make more medicines at home and improve the resiliency of supply chains while creating high paying jobs across sectors.

• Strengthening that capacity also means cutting regulatory barriers, speeding up FDA reviews and inspections, training skilled workers and supporting long-term investment in advanced manufacturing.

Where the United States relies on other countries for critical medicines or ingredients, policymakers can reduce supply chain vulnerabilities through targeted incentives and trusted supplier partnerships.

The goal: Grow U.S. manufacturing while maintaining diverse global supply chains and protecting U.S. national security and patient safety.

• Resilient supply chains depend on diversification, balancing domestic manufacturing growth with international partnerships and scientific collaboration.

Huntsville's legacy of scientific innovation and manufacturing prowess started long before this investment.

• Alabama has seen transformative investments before. Mercedes-Benz's $300 million commitment in 1993, roughly $700 million today, became such a turning point that major economic development projects in Alabama are still called "Mercedes moments."

At Axios' recent Beyond the Breakthrough: Huntsville's Biotech Rise event, PhRMA senior vice president of public affairs Alex Schriver drew parallels between Alabama's automotive boom and its emerging biopharmaceutical industry.

• "I really see what Eli Lilly is doing as Alabama's next Mercedes moment, right? A $6 billion investment. Our member companies have announced in the past year over $500 billion in new and expanded investment around the country to bring medicine development back to the United States and produce those medicines here in America. And it's transformative. Over 100,000 new jobs."

Lilly's proposed $6 billion Huntsville investment is about nine times larger than Mercedes' original commitment in today's dollars. While Mercedes transformed Alabama's automotive sector, Lilly has the potential to do something similar for advanced pharmaceutical manufacturing.

The impact: That growth translates into jobs and economic activity.

• Alabama's biopharmaceutical sector already supports over 21K jobs, including over 5.5K direct jobs, and generates $6.4 billion in economic output, according to research by TEConomy Partners prepared for PhRMA.

New manufacturing investment is adding to that footprint. Lilly expects its Huntsville facility to create 450 permanent jobs for engineers, scientists, operations personnel, lab technicians and others, while construction is expected to support another 3,000 jobs.

• For every $1 Lilly invests, the company estimates up to $4 in additional local economic activity.
• Each new manufacturing job is also expected to support additional jobs across supply chain, logistics and retail.

Plus, plus, plus: Decades of work in rocketry and space exploration have built a deep bench of scientists, engineers and advanced manufacturing expertise in Huntsville. That foundation is increasingly supporting biotechnology and life sciences.

• The city is home to the HudsonAlpha Institute for Biotechnology, a genomics and genetics research institute whose campus includes more than 45 biotech companies. The University of Alabama in Huntsville conducts research with partners ranging from NASA to the National Institutes of Health and collaborates with HudsonAlpha scientists and entrepreneurs.

• Organizations including Southern Research, a leader in American scientific research, and Bio Alabama, a nonprofit bioscience advocate, add to a regional network that helps move scientific discoveries forward, develop skilled talent and attract biopharma investment.

What this means: Regions with strong research institutions, skilled talent, manufacturing capabilities and industry collaboration can compete for investment and become new centers of biopharma activity.

Huntsville is a clear example. The concentration of science, engineering and manufacturing expertise that helped build the Rocket City is now supporting its growth in biotechnology and medicine manufacturing.

Here's what else: Huntsville's emergence comes as biopharma companies make broader investments in American manufacturing. $500 billion in new biopharmaceutical investment will give a $1.2 trillion boost to America's economy.

Some examples:

• Amgen has invested more than $40 billion in U.S. manufacturing and R&D, with recent investments in California, Ohio, North Carolina and Puerto Rico.
• Astellas is expanding its U.S. footprint with gene therapy manufacturing in North Carolina and new innovation centers in Massachusetts and California.
• AstraZeneca announced $50 billion in U.S. investment by 2030, building on America's medicines manufacturing and R&D capabilities.

The takeaway: Huntsville represents something bigger than a new manufacturing facility.

• Its growth shows how biopharma can expand into new parts of the country, bringing investment and high-value jobs to regions with the scientific talent, manufacturing expertise and research ecosystem to support them.

Looking ahead: Policymakers should make the U.S. the world's most attractive place to discover and develop innovative medicines. That means supporting domestic investment, modernizing regulations and building the skilled workforce needed to grow advanced manufacturing.

With the right policies and collaboration, emerging hubs like Huntsville can help strengthen medicine supply chains while sustaining America's leadership in biopharmaceutical innovation.

Learn more about Huntsville's role as an emerging biopharmaceutical hub.